Erratum
for
Liberato et al., J Clin Oncol 25 (6) 625-633.
Journal of Clinical Oncology, Vol 25, No 25 (September 1), 2007: pp. 4030
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.6267
ERRATUM
The February 20, 2007, article by Liberato, Marchetti, and Barosi, entitled "Cost Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer" (J Clin Oncol 25:625-633, 2007) contained errors.
In Table 1, in the row heading for Disease free/Never received adjuvant trastuzumab/Any relapse, the value for 13-60 months was given as 11%/yr, whereas it should have been 11%.
In Table 2, under the United States/Description and Reference column, the footnote for Echocardiography referred to, "Ramipril 0.67/d, metoprolol 0.43/d, two medical visits ( 25.8), one echocardiography," whereas it should have been, "Medicare reimbursement for CPT 93,307, 93,320, and 93,325."
The corrected Table 2 is reprinted below in its entirety.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
|